FDA weighs peptide decision as critics warn of consumer scams
The report frames pending agency action on peptides against complaints about gray-market sellers marketing products to consumers.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 18 07:23 ETSource: streamlinefeed.co.ke
The wire
- 01An agency decision on peptides is reported as pending, with critics pointing to consumer-facing scams in the market.
- 02Any FDA categorisation would directly affect what 503A and 503B pharmacies can compound and what telehealth sellers can offer.
- 03Details of the ruling, its scope and its timing are not specified in the report.
From the source
Read at streamlinefeed.co.keFDA weighs peptide ruling as critics warn of consumer scams